Conservative management of delayed, multicomponent coagulopathy following rattlesnake envenomation

Christopher Camilleri, Steven Offerman, Robert Gosselin, Timothy E Albertson

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background. Crotaline Fab therapy is recommended for controlling local tissue effects, coagulation abnormalities, and other systemic signs following mild-to-moderate N American Crotaline envenomations. Occasionally, coagulation abnormalities emerge after control of tissue effects has been achieved. These coagulation changes range from minor, single parameter abnormalities to multicomponent, critical value derangements. The bleeding risk associated with these abnormalities is unknown, and dosing guidelines for Crotaline Fab therapy in treating coagulation abnormalities that are severe or delayed-in-onset have not been clearly established. Case Report. A 40-year-old man was envenomated in the right hand by a rattlesnake. Crotaline Fab therapy was started within 1 h of envenomation and arrest of edema progression was achieved by 48 h of admission. Although fibrinogen, platelet count, aPTT, and INR were all normal on initial assessment, hematologic changes were evolving over post-envenomation days 1 to 5 despite 32 vials of Crotaline Fab. The patient was transferred to our tertiary care center on the fifth postenvenomation day with a platelet count of 15,000/mm3 and unmeasurable values for fibrinogen, aPTT, and INR. The patient was managed with close observation alone, with no additional antivenom, and was discharged home on day 12 with no improvement in fibrinogen, aPTT or INR. Follow up lab assessment showed resolution of the hematologic effects sometime between day 17 and 37. Conclusion. We report a case of rattlesnake envenomation with profound, delayed hematologic effects that were resistant to 32 vials of Crotaline Fab given over post-envenomation days 1 to 4. After day 4, no further attempt was made to achieve normal lab indices using antivenom. Close observation alone may be adequate in cases of multicomponent, critical value coagulopathies following rattlesnake envenomation as long as there is no evidence of bleeding and local tissue effects and systemic effects have been adequately controlled.

Original languageEnglish (US)
Pages (from-to)201-206
Number of pages6
JournalJournal of Toxicology - Clinical Toxicology
Volume43
Issue number3
DOIs
StatePublished - 2005

Fingerprint

Crotalus
International Normalized Ratio
Coagulation
Fibrinogen
Antivenins
Platelet Count
Tissue
Platelets
Observation
Hemorrhage
Tertiary Care Centers
Edema
Therapeutics
Hand
Guidelines
Conservative Treatment

Keywords

  • Antivenom
  • Coagulopathy
  • CroFab
  • Crotaline envenomation
  • Rattlesnake bite

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

Conservative management of delayed, multicomponent coagulopathy following rattlesnake envenomation. / Camilleri, Christopher; Offerman, Steven; Gosselin, Robert; Albertson, Timothy E.

In: Journal of Toxicology - Clinical Toxicology, Vol. 43, No. 3, 2005, p. 201-206.

Research output: Contribution to journalArticle

@article{523f618c93a146dea6a5134d3c524441,
title = "Conservative management of delayed, multicomponent coagulopathy following rattlesnake envenomation",
abstract = "Background. Crotaline Fab therapy is recommended for controlling local tissue effects, coagulation abnormalities, and other systemic signs following mild-to-moderate N American Crotaline envenomations. Occasionally, coagulation abnormalities emerge after control of tissue effects has been achieved. These coagulation changes range from minor, single parameter abnormalities to multicomponent, critical value derangements. The bleeding risk associated with these abnormalities is unknown, and dosing guidelines for Crotaline Fab therapy in treating coagulation abnormalities that are severe or delayed-in-onset have not been clearly established. Case Report. A 40-year-old man was envenomated in the right hand by a rattlesnake. Crotaline Fab therapy was started within 1 h of envenomation and arrest of edema progression was achieved by 48 h of admission. Although fibrinogen, platelet count, aPTT, and INR were all normal on initial assessment, hematologic changes were evolving over post-envenomation days 1 to 5 despite 32 vials of Crotaline Fab. The patient was transferred to our tertiary care center on the fifth postenvenomation day with a platelet count of 15,000/mm3 and unmeasurable values for fibrinogen, aPTT, and INR. The patient was managed with close observation alone, with no additional antivenom, and was discharged home on day 12 with no improvement in fibrinogen, aPTT or INR. Follow up lab assessment showed resolution of the hematologic effects sometime between day 17 and 37. Conclusion. We report a case of rattlesnake envenomation with profound, delayed hematologic effects that were resistant to 32 vials of Crotaline Fab given over post-envenomation days 1 to 4. After day 4, no further attempt was made to achieve normal lab indices using antivenom. Close observation alone may be adequate in cases of multicomponent, critical value coagulopathies following rattlesnake envenomation as long as there is no evidence of bleeding and local tissue effects and systemic effects have been adequately controlled.",
keywords = "Antivenom, Coagulopathy, CroFab, Crotaline envenomation, Rattlesnake bite",
author = "Christopher Camilleri and Steven Offerman and Robert Gosselin and Albertson, {Timothy E}",
year = "2005",
doi = "10.1081/CLT-200053339",
language = "English (US)",
volume = "43",
pages = "201--206",
journal = "Clinical Toxicology",
issn = "1556-3650",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Conservative management of delayed, multicomponent coagulopathy following rattlesnake envenomation

AU - Camilleri, Christopher

AU - Offerman, Steven

AU - Gosselin, Robert

AU - Albertson, Timothy E

PY - 2005

Y1 - 2005

N2 - Background. Crotaline Fab therapy is recommended for controlling local tissue effects, coagulation abnormalities, and other systemic signs following mild-to-moderate N American Crotaline envenomations. Occasionally, coagulation abnormalities emerge after control of tissue effects has been achieved. These coagulation changes range from minor, single parameter abnormalities to multicomponent, critical value derangements. The bleeding risk associated with these abnormalities is unknown, and dosing guidelines for Crotaline Fab therapy in treating coagulation abnormalities that are severe or delayed-in-onset have not been clearly established. Case Report. A 40-year-old man was envenomated in the right hand by a rattlesnake. Crotaline Fab therapy was started within 1 h of envenomation and arrest of edema progression was achieved by 48 h of admission. Although fibrinogen, platelet count, aPTT, and INR were all normal on initial assessment, hematologic changes were evolving over post-envenomation days 1 to 5 despite 32 vials of Crotaline Fab. The patient was transferred to our tertiary care center on the fifth postenvenomation day with a platelet count of 15,000/mm3 and unmeasurable values for fibrinogen, aPTT, and INR. The patient was managed with close observation alone, with no additional antivenom, and was discharged home on day 12 with no improvement in fibrinogen, aPTT or INR. Follow up lab assessment showed resolution of the hematologic effects sometime between day 17 and 37. Conclusion. We report a case of rattlesnake envenomation with profound, delayed hematologic effects that were resistant to 32 vials of Crotaline Fab given over post-envenomation days 1 to 4. After day 4, no further attempt was made to achieve normal lab indices using antivenom. Close observation alone may be adequate in cases of multicomponent, critical value coagulopathies following rattlesnake envenomation as long as there is no evidence of bleeding and local tissue effects and systemic effects have been adequately controlled.

AB - Background. Crotaline Fab therapy is recommended for controlling local tissue effects, coagulation abnormalities, and other systemic signs following mild-to-moderate N American Crotaline envenomations. Occasionally, coagulation abnormalities emerge after control of tissue effects has been achieved. These coagulation changes range from minor, single parameter abnormalities to multicomponent, critical value derangements. The bleeding risk associated with these abnormalities is unknown, and dosing guidelines for Crotaline Fab therapy in treating coagulation abnormalities that are severe or delayed-in-onset have not been clearly established. Case Report. A 40-year-old man was envenomated in the right hand by a rattlesnake. Crotaline Fab therapy was started within 1 h of envenomation and arrest of edema progression was achieved by 48 h of admission. Although fibrinogen, platelet count, aPTT, and INR were all normal on initial assessment, hematologic changes were evolving over post-envenomation days 1 to 5 despite 32 vials of Crotaline Fab. The patient was transferred to our tertiary care center on the fifth postenvenomation day with a platelet count of 15,000/mm3 and unmeasurable values for fibrinogen, aPTT, and INR. The patient was managed with close observation alone, with no additional antivenom, and was discharged home on day 12 with no improvement in fibrinogen, aPTT or INR. Follow up lab assessment showed resolution of the hematologic effects sometime between day 17 and 37. Conclusion. We report a case of rattlesnake envenomation with profound, delayed hematologic effects that were resistant to 32 vials of Crotaline Fab given over post-envenomation days 1 to 4. After day 4, no further attempt was made to achieve normal lab indices using antivenom. Close observation alone may be adequate in cases of multicomponent, critical value coagulopathies following rattlesnake envenomation as long as there is no evidence of bleeding and local tissue effects and systemic effects have been adequately controlled.

KW - Antivenom

KW - Coagulopathy

KW - CroFab

KW - Crotaline envenomation

KW - Rattlesnake bite

UR - http://www.scopus.com/inward/record.url?scp=18744414503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18744414503&partnerID=8YFLogxK

U2 - 10.1081/CLT-200053339

DO - 10.1081/CLT-200053339

M3 - Article

VL - 43

SP - 201

EP - 206

JO - Clinical Toxicology

JF - Clinical Toxicology

SN - 1556-3650

IS - 3

ER -